Carcinoid Tumor Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Clinical Trials

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Conditions:   Small Intestinal NET;   Carcinoid Heart Disease Interventions:   Drug: Telotristat Ethyl;   Drug: Lanreotide Sponsors:   European Organisation for Research and Treatment of Cancer - EORTC;   Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2019 Category: Research Source Type: clinical trials